2M+ votes, S4 Best Creators wrap-up Congrats to the top 30, chosen by the community 🥇 @ZKSgu · 495,941 votes 🥈 @AirdropAlchemis · 213,947 votes 🥉 @vvickym2 · 203,127 votes 4️⃣ @bibisister0508 · 177,029 votes 5️⃣ @Kangzi_VC · 124,613 votes 6️⃣ @lizk_jp · 73,120 votes 7️⃣ @Joensmoon · 68,787 votes 8️⃣ @nancoasky · 68,284 votes 9️⃣ @kuzisatoshinin · 40,626 votes 🔟 @shuarix · 39,391 votes Appreciate everyone on the journey and the support. S5 continues

Hardy and Ramanujan’s most famous joint paper was in the theory of partitions, the ways of representing a given whole number n as the sum of positive whole numbers. The number 5, for example, can be “partitioned” seven ways: 5 = 5 5 = 4 + 1 5 = 3 + 2 5 = 3 + 1 + 1 5 = 2 + 2 + 1 5 = 2 + 1 + 1 + 1 5 = 1 + 1 + 1 + 1 + 1 As n grows, the number of partitions balloons. For n = 10, there are 42. For n = 50, there are 204,226. For n = 100, there are 190,569,292. And for n = 200 there are 3,972,999,029,588. In 1918, in a forty-page paper on partition theory, Hardy and Ramanujan offered a surprisingly accurate asymptotic formula for the number of partitions of an integer n. In 1942, Erdős was able to show that Hardy and Ramanujan didn’t need to use heavy machinery to deduce the first term of their formula, that the term could be found by “elementary” methods. Elementary techniques are not necessarily simpler. In this context, elementary means that the proof of the formula relies on a restricted set of numbers, the so-called real.

$CAPR says Deramiocel’s BLA remains under active FDA review and it continues to see a path to approval despite the 3-9 AdCom vote. Capricor also ended Q2 with ~$238M in cash and says it has enough liquidity to fund operations for at least the next 12 months, reducing near-term financing concerns. The company highlighted that HOPE-3 met its primary upper-limb endpoint at p=0.029, while the AdCom was not asked to vote on that endpoint or overall benefit-risk. A regulatory update is expected on today’s 4:30 PM ET call.

🔥 Wildfires and landscape fires area burnt YTD as of August 1, 2026 (hectares): 1. 🇨🇩 DR of Congo: 13,611,126 2. 🇦🇺 Australia: 11,801,650 3. 🇦🇴 Angola: 7,473,034 4. 🇸🇸 South Sudan: 6,955,022 5. 🇨🇫 Central African Republic: 6,017,881 6. 🇲🇲 Myanmar: 4,325,702 7. 🇮🇳 India: 4,029,704 8. 🇷🇺 Russia: 3,335,029 9. 🇬🇳 Guinea: 3,250,992 10. 🇿🇲 Zambia: 3,213,687 11. 🇻🇪 Venezuela: 2,977,466 12. 🇳🇬 Nigeria: 2,807,200 13. 🇹🇭 Thailand: 2,669,550 14. 🇱🇦 Laos: 2,641,321 15. 🇺🇸 United States: 2,371,207 16. 🇨🇳 China: 2,265,057 17. 🇨🇦 Canada: 2,031,754 18. 🇧🇷 Brazil: 2,030,209 19. 🇪🇹 Ethiopia: 1,851,131 20. 🇬🇭 Ghana: 1,763,395 21. 🇰🇭 Cambodia: 1,525,312 22. 🇲🇱 Mali: 1,490,698 23. 🇨🇲 Cameroon: 1,435,373 24. 🇹🇩 Chad: 1,309,155 25. 🇲🇽 Mexico: 1,264,823 Source: Global Wildfire Information System (GWIS) via Our World in Data

GOOGLE $GOOGL JUST UPDATED ITS STOCK PORTFOLIO This is everything Google owned as of the end of Q2 SpaceX $SPCX: 551,189,500 shares Planet Labs $PL: 35,248,893 shares AST SpaceMobile $ASTS: 8,943,486 shares CME Group $CME: 3,484,020 shares ARM Holdings $ARM: 1,960,784 shares Revolution Medicines $RVMD: 2,946,619 shares Freshworks $FRSH: 16,206,643 shares Parabilis Medicines $PRBX: 4,919,498 shares Tempus AI $TEM: 1,551,102 shares GitLab $GTLB: 2,724,712 shares UiPath $PATH: 7,034,337 shares Ethos Technologies: 3,622,604 shares Prime Medicine $PRME: 16,562,498 shares Fervo Energy: 1,760,732 shares PayPay Corp: 3,125,000 shares Maze Therapeutics $MAZE: 1,388,583 shares Relay Therapeutics $RLAY: 1,410,029 shares BridgeBio Oncology Therapeutics $BBOT: 2,823,126 shares Oscar Health $OSCR: 481,988 shares Beam Therapeutics $BEAM: 321,604 shares Vera Therapeutics $VERA: 241,264 shares Sana Biotechnology $SANA: 2,812,500 shares Monte Rosa Therapeutics $MRSN: 372,474 shares Lyell Immunopharma $LYEL: 293,256 shares Figma $FIG: 215,582 shares Spero Therapeutics $SPRO: 889,979 shares Hyperfine $HYPR: 898,720 shares Autolus Therapeutics $AUTL: 698,262 shares

🚀BITCOIN IS GOING TO ABSOLUTELY MOON🚀 The last time Bitcoin’s 200-day moving average crossed BELOW its 200-week moving average, every chart goblin on Earth began measuring the coffin. Bitcoin was $20,590. Exactly 492 days later, it reached $73,121. That was a 3.55x. A 255.13% return. Today: Bitcoin: $63,647 200-day SMA: $71,729 200-week SMA: $63,552 The averages are now $8,178 apart and converging rapidly. If Bitcoin traded completely flat, they would cross around November 2, 2026. Only then would the historical clock begin. Apply the previous move over the exact same 492-day window following that crossover: $63,647 → $226,029 November 2, 2026 → March 8, 2028 History owes us nothing. But the last time this “bearish” crossover appeared, Bitcoin had already finished digging the grave, buried the sellers inside it, and quietly installed a launchpad over the cemetery. Sometimes the death cross is the starting gun:

Three major on-chain liquidation zones on $ETH. Trend Research holds 356,150 $ETH($671M), with liquidation prices between $1,562 and $1,698. Joseph Lubin and two unknown whales hold 293,302 $ETH($553M), with liquidation prices between $1,329 and $1,368. 7 Siblings holds 286,733 $ETH($541M), with liquidation prices at $1,075 and $1,029.

Capricor Therapeutics faces an FDA target date on Saturday for a Duchenne muscular dystrophy therapy. On 13th August its chief executive closed the quarterly call by declining to take questions. “Lastly, due to the sensitivity of our ongoing discussions with the Food and Drug Administration, we are not holding a Q&A today.” The next day Capricor filed its quarterly report. The leases note carries a date that says what management expects. It signed a San Diego headquarters lease on 9th July that either side can terminate if the FDA has not approved by 31st December. To value it, Capricor had to pick a date on which the approval question resolves. It picked 22nd August 2026, which the filing calls “management’s best estimate of the date on which the FDA approval contingency will be resolved.” A $76.3 million right of use asset rests on that assumption. The same filing cuts against that. Capricor plans to submit an amendment with 24 month data, and says the FDA “has indicated it is willing to review this amendment and, upon receipt, to extend the PDUFA action date accordingly.” That amendment has not been disclosed as submitted. The lease note was not adjusted for the possibility. On 29th July an advisory committee voted 9 to 3 that the evidence did not establish effectiveness for the heart condition. The vote was narrow, was not on the trial’s main result, and is not binding. Two weeks later, after peer review, Capricor restated the heart measure from p 0.04 to p 0.09. Because it sat above the others in the prespecified testing order, everything below it is now reported as nominal. The primary upper limb result, p 0.029, was unaffected. A PDUFA date is a user fee goal, not a legal deadline, and the FDA does not publish extensions. Only the company can say where it stands. It last said anything on 14th August.